Sunshine Guojian Pharmaceutical (Shanghai) Co (688336) Fair Value & Analysis
Healthcare · CN · Market cap 34.7B CNY
Fair value as of: Jul 12, 2026
From 25 valuation models · updated today
Share price −4.7% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥40.15 – ¥92.30 · fair‑value band ¥62.25 – ¥206.90 · the ¥52.80 price screens below the ¥128.51 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sunshine Guojian Pharmaceutical (Shanghai) Co (688336) currently trades at ¥52.80, while our model-based Fair Value estimate is ¥128.51 — implying the stock looks roughly 143.4% undervalued today. We read business quality at 67/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Sunshine Guojian Pharmaceutical (Shanghai) Co generated revenue of 4.3B CNY at a net margin of 68.9%. Revenue grew 38.6% year over year. It earns a return on equity of 41.8%. The balance sheet holds a net cash position of 409M CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥62.25 (bear case) to ¥206.90 (bull case); at ¥52.80, the current price sits below that range. The share trades about 45% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -23% fair-value upside — at 143%, 688336 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company was founded in 2002 and is based in Shanghai, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sunshine Guojian Pharmaceutical (Shanghai) Co reported revenue of ¥4.2B in FY2025 versus ¥929M in FY2021, a compound +45.8%/yr. Reported net income was ¥2.9B in FY2025, compounding +257.2%/yr from FY2021.
Is 688336 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (688336) undervalued?
What is the fair value of 688336?
What is the quality score of 688336?
What is the revenue of Sunshine Guojian Pharmaceutical (Shanghai) Co (688336)?
What is the net profit margin of 688336?
Does Sunshine Guojian Pharmaceutical (Shanghai) Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Sunshine Guojian Pharmaceutical (Shanghai) Co analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.